Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.38 (market cap $29.60B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.22. Which is the better fit depends on your goals.
| ALNY | VCIT | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $84.82 |
52-Week Low | $205.48 | $81.07 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.225 with a modest 0.19% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.34 and $0.33. Recent financial media coverage highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to similar bond ETFs.
The outlook for VCIT remains balanced with income generation as the primary appeal, though technical weakness suggests near-term pressure. Investment opportunities include attractive yield relative to Treasury alternatives and low expense structure. Risks include interest rate sensitivity and corporate credit quality concerns in changing economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
